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Case presentation
A 46-year-old woman was admitted to the metabolic ward of
New England Medical Center Hospital (NEMCH) for evaluation
of hypokalemia and metabolic alkalosis. The patient was in good
health until four months earlier, when preoperative determina-
tion of serum electrolytes disclosed a serum potassium concen-
tration of 3.0 mEq/liter and a bicarbonate concentration of 31
mEq/liter. A hysterectomy was performed without complica-
tions, and on discharge 80 mEq of potassium chloride per day
was prescribed. One month later she was admitted to another
hospital because of supraventncular tachycardia; hypokalemia
had persisted. Evaluation revealed no evidence of organic heart
disease and the arrhythmia was presumed to be secondary to
hypokalemia.
Two weeks later, she was readmitted for further evaluation.
Blood pressure was 120/80 mm Hg; cardiac examination revealed
normal S1 and S2 sounds and a grade 1/VI systolic ejection mur-
mur at the lower left sternal border; abdominal examination re-
vealed no abdominal masses; no edema was present. The re-
mainder of the physical examination was normal. Laboratory
findings revealed: serum creatinine, 0.7 mg/dl; BUN, 15 mg/dl;
serum sodium, 138 mEq/liter; serum potassium, 2.9 mEq/liter;
chloride, 96 mEq/liter; and bicarbonate, 34 mEq/liter; hemo-
gram, serum calcium, serum phosphorus, serum albumin, serum
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bilirubin, blood glucose, serum uric acid, and transaminase lev-
els were normal. Peripheral plasma renin activity on a diet
containing 80 mEq of sodium was 3.5 ng/ml/hour; 24-hour uri-
nary aldosterone excretion was 32 ng. An intravenous pyelogram
and barium enema were normal. Therapy with 100 mg of spirono-
lactone per day was initiated, and potassium chloride (100 mEq
per day) was continued.
Although the serum potassium concentration initially rose to
3.4 mEq/liter, within two weeks it fell again to 2.8 mEq/Iiter. The
dose of potassium chloride was increased to 180 mEq/day and on
this regimen, the serum potassium concentration varied between
3.2 and 3.5 mEq/liter. Within several weeks, however, the serum
potassium concentration fell to 3.1 mEq/liter. Potassium chloride
was increased to 200 mEq/day, spironolactone was discontinued,
and 80 mg of triamterene per day was added to the regimen but
was soon discontinued because the patient developed head-
aches.
On admission to NEMCH, physical examination revealed the
blood pressure to be 128/84 mm Hg supine and 125/80 mm Hg
upright. Laboratory findings were: hemoglobin, 12.5 g/dl;
hematocrit, 38%; white blood cell count, 6900/mm3 with 48%
polymorphonuclear leukocytes, 47% lymphocytes, and 3 mono-
cytes; serum creatinine, 0.8 mgldl; BUN, 15 mgldl; serum so-
dium, 142 mEq/liter, serum potassium, 2.7 mEqlliter; serum
chloride, 98 mEq/liter; and serum bicarbonate, 32 mEq/liter.
Serum magnesium was 1.3 mEq/liter. Excretions of 17-hydroxy-
corticosteroids and 17-ketosteroids were normal. Toxicologic
screening for diuretic agents was negative.
Results of the metabolic balance studies in consecutive 5-day
periods are given in Table 1. All measurements were made on the
fourth to fifth day of the respective dietary regimen.
Following period IV, potassium intake was reduced to 70
mEq/day; sodium intake remained at 10 mEq/day. The patient
began to lose weight and after 3 days noted dizziness when
standing. On physical examination, her blood pressure fell from
118/70 to 88/55 mm Hg, and her pulse rate increased from 90 to
120 beats per minute on standing; therefore one liter of normal
saline was administered intravenously over 6 hours, and oral so-
dium and potassium intake were increased to 250 to 270 mEq/
day, respectively. This change in intake increased her blood
pressure to 120/80 mm Hg without orthostatic changes and
caused a weight gain of approximately 2 kg. Serum potassium
was 2.9 mEq/liter. No data were collected during this interval
because the patient did not attain a steady state.
Following period V she was allowed unrestricted sodium chlo-
ride intake, and indomethacin (150 mg/day) was continued. After
4 days the serum potassium was 3.6 mEq/liter and she was dis-
charged from the hospital. She continued to take indomethacin
but was not given potassium supplementation.
The patient felt well and continued taking indomethacin, but
the drug was stopped 18 months later because she developed up-
per gastrointestinal bleeding. Ibuprofen was substituted for indo-
methacin at that time and potassium chloride, 60 mEq/day, was
added to the regimen. This treatment has been continued for an
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Table 1. Summary of patient data
Perioda I II III IV V
Dietary regimen
Intake (mEq/day)
Sodium 100 250 250 10 100
Potassium 70 70 270 270 70
Medications none none none none indomethacin
(150 mg/day)
3.5
Serumpotassium(mEq/liter) 2.4 2.6 2.8 2.8 2.7
Serum bicarbonate (mEq/liter) 30 30 28 30
Plasma renin activity
(ng/mllhour)
Supine 7.8 3.2 2.1 6.8 1.16
4 hours upright 32.9 17.0 10.3 15.8 10.4
Aldosterone
Plasma (ngldl) 3.3 <3.0 3.0 9.7 <3.0
Urine (pg/day) 67.3 60 128 434 19.6
Urinary prostaglandins
ng/day)
PGE2 371 269 318 521 31
PGF2. 513 256 371 653 —
Angiotensin infusion test 90 — 29 — 19
(quantity of angiotensin II
required to raise
diastolic BP 20 mm Hg)
(ng/kg/min)
a Between periods IV and V the patient developed transient postural hypotension, and detailed observations could not be made (see
text).
b Analyses carried out in the laboratory of Dr. Michael Dunn at Case-Western Reserve University School of Medicine.
Discussion
DR. MICHAEL J. DUNN (Director, Division of
Nephrology, University Hospitals of Cleveland,
and Hanna Payne Professor of Medicine, Case-
Western Reserve University, Cleveland, Ohio): I
plan to develop the case that prostaglandin over-
production is merely a secondary phenomenon in
Bartter's syndrome, and that it is not the proxi-
mal cause of most of the clinical and physiologic
features of this entity. In doing so, I will con-
sider the biochemistry and physiology of prosta-
glandins, the observations on plasma and urinary
prostaglandins in patients with the syndrome, the
possible mechanisms of prostaglandin over-
production, and the nature of the disturbance of the
renin-angiotensin-aldosterone systems in these pa-
tients.
Biochemistry and physiology of prostaglandins.
In order to discuss the role of prostaglandins in
Bartter's syndrome, we should review the biochem-
istry and physiology of prostaglandins in the kid-
ney. Figure 1 summarizes the biochemical path-
ways for prostaglandin synthesis in the kidney [1-
additional 18 months. Aside from a recurrence of supra-
ventricular tachyarrhythmia treated effectively with digitalis and
propranolol, the patient has remained well. Serum potassium has
ranged from 3.4 to 3.7 mEq/liter.
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Fig. 1. Renal conversion of arachidonic acid to proslaglandins, thromboxanes and other products. The existence of the lipoxygenase
products is unproved in the kidney.
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3]. The substrate, arachidonic acid, is a 20-carbon
fatty acid with 4 double bonds (C20:4). Arachidonic
acid is stored within cells as phospholipid, choles-
terol, or triglyceride esters. In the kidney, phos-
pholipids, especially phosphatidyicholine, are the
largest reservoirs of arachidonic acid. Control of
the availability of arachidonic acid is an important
regulator of prostaglandin biosynthesis. Virtually
all known stimuli of prostaglandin synthesis in-
crease the release of arachidonate from phospho-
lipids rather than directly increase cyclooxygenase
activity. Release of arachidonate from phospholip-
ids requires deacylation of an ester linkage, and
this deacylation is controlled by phospholipase A2.
Steroidal antiinflammatory drugs, such as predni-
sone or dexamethasone, partially inhibit phospholi-
pase. After release of arachidonic acid from phos-
pholipids, the arachidonate is either reacylated to
the phospholipid or is oxygenated via the cy-
clooxygenase and lipoxygenase pathways. Fatty
acid cyclooxygenase, primarily found in endo-
plasmic reticulum, dioxygenates arachidonic acid to
the labile prostaglandin endoperoxides. Aspirin, in-
domethacin, meclofenamate, ibuprofen, naproxen,
tolmetin, phenylbutazone, fenoprofen, and other
nonsteroidal antiinflammatory drugs all inhibit fatty
acid cyclooxygenase. Whereas aspirin irreversibly
acetylates the cyclooxygenase, the other drugs re-
versibly inhibit the enzyme. Cyclooxygenase turn-
over is rapid in the kidney; the inhibitory effects of
these drugs therefore is brief, and normal prosta-
glandin synthesis returns within 12 to 36 hours after
administration of the nonsteroidal antiinflammatory
drug is discontinued. Although lipoxygenase has
been found in platelets and granulocytes, it is uncer-
tain whether lipoxygenase exists in the kidney.
Lipoxygenase products include the hydroxy fatty
acids and the leukotrienes. The hydroxy fatty acids
are chemotactic to leukocytes, and the leukotrienes
contract vascular and bronchial smooth muscle
(slow-reacting substance of anaphylaxis is a leuko-
triene) [4]. The prostaglandin (PG) endoperoxides
are enzymically converted to PGE2, PGF2,, PGD2,
PG!2 (pro stacyclin), and thromboxane A2 (TxA2).
The more stable products, PGE2, PGF2, and PGD2,
have been recognized for many years as normal
renal prostaglandins. Only recently have PG!2 and
TxA2 been demonstrated as products of cy-
clooxygenase in normal human and animal kidneys
[5].
The kidney is anatomically and physiologically a
complex organ, and it is not surprising that prosta-
glandin synthesis varies greatly among different
Table 2. Renal sites of prostaglandin synthesis
Tissuea Relative amounts synthesized"
Medullary interstitial cells [61 PGE2 ' PGF2a. No PGI2 or TxA,
Collecting tubules (papillary)
[7] PGE2 > PGI2 > PGF2a > POD2
Cortical tubules (proximal
and distal) [8] POE2 > PGF2,. > TxA2 ? PGI2
Cortical arterioles [9] PGI2 > PGF2a> POE2
Glomeruli [8] PGE2 PGF, > TxA2>
P012 = PGDZ
a In vitro studies of isolated portions of the kidney or of cells in
culture.
b These measurements are approximate, especially when made
by radiometric thin-layer chromatography. The in vivo synthesis
of these products can differ substantially because of cofactors,
substrate concentration, etc.
portions of the nephron. Overall, prostaglandin syn-
thesis, expressed per milligram of tissue protein, is
greatest in the papilla and medulla and least in the
outer cortex. However, one should not conclude
that the physiologic importance of cortical prosta-
glandins is minor; I will return to this topic later.
Table 2 summarizes the current knowledge about
prostaglandin and thromboxane synthesis in dif-
ferent portions of the kidney. Specific renal prosta-
glandins probably are synthesized by the same cells
in which the prostaglandins exert a physiologic ac-
tion. In other words, the prostaglandins act directly
at their nephron site of synthesis. The measurement
of prostaglandins in urine or renal venous blood in-
dicates only total renal synthesis. Obviously it is
difficult, if not impossible, to surmise from these
measurements the relative contributions of glomer-
uli, tubules, interstitial cells, etc. to the urinary and
renal venous prostaglandin concentrations. We can
safely assume, however, that practically all renal
venous and urinary prostaglandins originate in the
kidney, excluding platelet and granulocyte artifact
in blood and contamination of urine with seminal
fluid. Therefore, the increased urinary levels of
prostaglandins in patients with Bartter's syndrome
indicates renal overproduction of the measured
prostaglandin. Increased prostaglandin synthesis in
Bartter's syndrome certainly occurs in the medul-
lary interstitial cells and probably in glomeruli and
cortical vessels as well.
Prostaglandins and thromboxanes exert multiple
physiologic and pharmacologic actions in the kid-
ney. Table 3 summarizes the best-established renal
actions of these compounds [3]. Some of these
actions probably are unimportant in normal physio-
logic processes. For example, inhibition of prosta-
glandin synthesis has no effect on renal blood flow
or glomerular filtration in normal conscious animals
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Table 3. Renal actions of prostaglandins
1. Renal blood flow
a. Vasodilation: PGE,, PG!2
b. Vasoconstriction: TxA2; PGF2a (weak)
2. Glomerular filtration rate a
a. Increase: PGE2, PG!2
b. Decrease: TxA2
3. Renin secretion
a. Increased: PGI2, PGE2, PGD2
b. Decreased: ? TxA2
4. Natriuretic: PGE2, PGI2, PGD2?
5. Water diuretic: PGE2
a Increments of GFR only occur if vasoconstriction (e.g., re-
sulting from angiotensin II) precedes administration of PGE2 or
PG!2.
or humans, but the same drugs can reduce signifi-
cantly renal blood flow and filtration rate if renal
vasoconstriction is present [10]. Therefore angio-
ten sin II, catecholamines, and alpha-adrenergic
neural input apparently elicit a compensatory in-
crement of renal prostaglandin production that par-
tially counteracts the renal vasoconstriction. Indo-
methacin therapy in patients with Bartter's syn-
drome generally reduces the glomerular filtration
rate and presumably lowers renal blood flow. The
renin-stimulatory effects of PG!2 and PGE2 might
account partially for the renin overproduction in
Bartter's syndrome. The importance of prostaglan-
dins as regulators of sodium and water excretion is
unknown. Although PGE2 has unequivocal natri-
uretic and diuretic potency, it seems that other endo-
crine as well as physical factors exert a more potent
and controlling influence over sodium and water ex-
cretion. Inhibition of renal prostaglandin synthesis
does not completely eliminate the renal losses of
chloride or potassium in patients with Bartter' s syn-
drome.
Some characteristics of Bartter's syndrome. Be-
fore discussing some of the important features of
this patient's illness, I would like to summarize the
usual findings in Bartter's syndrome [11-13]. These
patients have hypokalemia and hypochloremic alka-
losis, both of which are refractory to potassium re-
placement therapy. Plasma renin activity is in-
creased, and angiotensin II and aldosterone levels
are elevated. Hyperuricemia and hypomagnesemia
sometimes are present. Growth is retarded in chil-
dren. The renal juxtaglomerular cells become hy-
perplastic, as can the renal medullary interstitial
cells. The pressor response to angiotensin II is
blunted although the patient is normotensive. Uri-
nary prostaglandins are generally, but not in-
variably, increased, whereas plasma PGE2 and
PGF2Q levels are normal. Renal chloride wasting,
presumably due to a chloride-reabsorption defect in
the thick ascending limb of Henle's loop, has been
documented. Most of the signs and symptoms of
Bartter's syndrome are secondary to severe, chron-
ic potassium depletion and include weakness, ma-
laise, muscle cramping, polyuria, and nocturia.
Treatment, although helpful, is not curative. Thera-
peutic measures include potassium supplements,
spironolactone, triamterene, propranolol, indo-
methacin, and ibuprofen [11-13].
Several unusual aspects of this case make suspect
the diagnosis of Bartter's syndrome in this patient.
In most patients with Bartter's syndrome, the dis-
ease is symptomatic and has been diagnosed by
the time the patient is 25 years old [11]. Patients
have been reported, however, in whom the diagno-
sis was not established until age 35, 41, or 52 years.
The patient under discussion would be the second-
oldest, at the time of diagnosis, in the literature. An-
other unusual feature was her lack of symptoms.
Very few cases are discovered incidentally, without
the patient complaining of weakness, cramps, and
polyuria [12]. It is also atypical for a patient with
Bartter' s syndrome to develop severe sodium de-
pletion with postural hypotension after sodium re-
striction, as occurred between periods IV and V
(see Table 1). These factors—namely age at onset,
lack of symptoms, and postural hypotension—make
it imperative that we rule out surreptitious vomiting
or diuretic abuse as an explanation for this woman's
clinical disorder.
Observations about prostaglandins. In 1976 and
early 1977, four papers appeared that stimulated in-
terest in the possible pathophysiologic importance
of prostaglandins in Bartter's syndrome. Fichman
and coworkers reported that indomethacin reduced
plasma renin activity and aldosterone levels, de-
creased renal losses of sodium and potassium, re-
versed the pressor resistance to angiotensin II, and
increased serum potassium [14]. Although they
measured an increased blood concentration of
PGA2 in their patient who had Bartter's syndrome,
this value represented radioimmunoassay artifact,
because PGA2 is not measurable in human plasma
[15]. Verberckmoes et al also successfully treated a
patient with indomethacin and improved the hyper-
reninemia, hyperaldosteronism, and the hypoka-
lemia [16]. They observed histologic hyperplasia of
the renal medullary interstitial cells, cells that have
been found to produce large quantities of prosta-
glandins, especially PGE2 [6]. Verberckmoes et al
hypothesized that renal prostaglandins, synthesized
by the hyperplastic medullary interstitial cells, ac-
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counted for most of the changes in endocrine and
electrolyte status in their patient [16]. Donker and
coworkers reached similar conclusions after treating
3 patients with indomethacin [17]. Gill and col-
leagues, using radioimmunoassay and gas chroma-
tography-mass spectroscopy, verified that renal ex-
cretion of prostaglandins is enhanced in patients
with Bartter's syndrome [18]. Urinary PGE2 was
increased in 4 patients, whereas a metabolite of
PGE2, attributable to systemic (i.e., nonrenal) pro-
duction and degradation of PGE2, was not increased.
Indomethacin or ibuprofen decreased urinary ex-
cretion of PGE2 by 66% to 96% and partially re-
versed the biochemical abnormalities of the syn-
drome [18]. Subsequently, many investigators have
confirmed both the presence of increased excretory
rates for prostaglandins and the improvement after
therapy with nonsteroidal inhibitors of prostaglan-
din synthesis [19-27]. Twenty-four children and
adults (20 females and 4 males) in 5 separate reports
had moderate (twofold) to marked (tenfold) incre-
ments of urinary PGE2 [20-24]. Also, PGD2 and 6-
keto-PGF1, the stable degradation product of PGI2,
were increased in the urine of 5 women with Bartter's
syndrome [28]. Urinary 6-keto-PGF1a probably pro-
vides a reasonable measure of renal PG!2 synthesis
[29, 30]. Cortical and medullary microsomes ob-
tained from human kidneys synthesize large quanti-
ties of 6-keto-PGF1c. and PGF2. but lesser amounts
of PGE2 and TxA2 [5]. In patients with Bartter's
syndrome, therefore, overproduction of PGI2 as
measured by increased excretion probably occurs in
the renal medulla as well as in the cortex. These
findings gain significance in light of the recently de-
scribed changes in platelet aggregation and the po-
tent renin-stimulatory actions of PGI2. Although
most investigators have documented raised levels of
urinary PGE2, this increase is not an invariable find-
ing. Dray observed that urinary excretion of PGE2
and PGF2a was normal in 7 adults with the syndrome,
whereas 8 children had three- to fourfold elevations
of urinary PGE2 and PGF2a [31]. Peripheral venous
plasma concentrations of PGE2 and PGF2c, were
normal in the children and the adults [31]. This lat-
ter observation reinforces an earlier report by Gill
et al, who found normal excretion of a PGE metabo-
lite to be an index of circulating PGE2 rather than of
renal PGE2 [18]. Stoff and coworkers [21] and
O'Reagan et al [32] observed defects in platelet ag-
gregation in patients and parents of patients with
the syndrome. Platelet aggregation, measured in
vitro with platelet-rich plasma, was abnormal in re-
sponse to ADP, collagen, and epinephrine. Therapy
with indomethacin for 3 to 5 days substantially im-
proved the aggregation responses and reduced the
abnormally high levels of cyclic AMP in the plate-
lets [21]. Normal platelets acquired the aggregation
defect after they were incubated in plasma from pa-
tients with Bartter's syndrome, but the stability of
the unknown plasma factor ruled out PG!2 as the
explanation. In fact, researchers disagree as to
whether PGI2 is a circulating "hormone" at all [33,
34]. Both PGD2 and 6-keto-PGE1 are stable prosta-
glandins with potent actions on platelet adenylate
cyclase and aggregation, and these characteristics
could explain the in vitro results [35, 36].
In the patient under discussion, excretion of
PGE2 and PGF2. was normal or slightly increased.
We measured these prostaglandins using radioim-
munoas say after acidification, solvent extraction,
and silicic acid-column chromatography [37]. Nor-
mal 24-hour excretion of PGE2 and PGF2,. ranges
from 150-300 and 400-700 nglday, respectively, us-
ing this method. Therefore, the values for PGE2 ex-
cretion were clearly increased only in period IV,
during sodium restriction. Plasma levels of PGE2
and PGF2a were normal or undetectable on most of
our determinations in this patient.
Overproduction of prostaglandins: Cause or ef-
fect? Is overproduction of prostaglandins, espe-
cially renal prostaglandins, a primary or a secondary
abnormality in Bartter's syndrome? In my opinion,
increased prostaglandin synthesis is a secondary
phenomenon (Table 4). If it were a primary abnor-
mality, one would expect all patients to have en-
hanced synthesis, excretion, or both, of prostaglan-
dins. However, some patients have no detectable
abnormalities of prostaglandin excretion. Treat-
ment with indomethacin or ibuprofen reduces pros-
taglandin excretion to subnormal levels, yet the
clinical syndrome is only partially reversed [19]. If
prostaglandins played a primary and central role,
then the efficacy of cyclooxygenase-inhibitor drugs
would be greater. Gill and Bartter concluded that a
reabsorptive defect for chloride transport in the as-
cending limb of Henle's loop is the basic abnormal-
ity in patients with the syndrome [38]. Theoretical-
ly, prostaglandins could account for this reabsorp-
tive defect, since (1) PGE2 inhibits chloride
reabsorption in microperfused tubular segments of
the thick ascending limb of Henle's loop in the rab-
bit, and (2) inhibitors of prostaglandin synthesis
augment tubular chloride reabsorption [39, 40].
However, the chloride reabsorptive defect persists
after indomethacin or ibuprofen treatment despite a
reduction in renal prostaglandin synthesis [20, 38].
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Table 4. Renal overproduction of prostaglandins: A secondary
event in Bartter's syndrome
1. Increased prostaglandin excretion is a variable finding
2. Reduction of prostaglandin synthesis, after indomethacin
treatment, is not curative
3. Tubular reabsorptive defect for chloride is not improved by
indomethacin-
4. Vomiting and diuretic abuse mimic Bartter's syndrome, with
increased excretion of PGE2 present in all three conditions
Patients with Bartter's syndrome can be dif-
ferentiated from patients who vomit covertly: urine
chloride levels are quite high in the former [38] and
low in the latter group [41]. The chloride determina-
tion in today's patient favors a diagnosis of Bart-
ter's syndrome or diuretic abuse, as the urine chlo-
ride was approximately equal to the chloride intake.
Diuretic abuse seems unlikely because the urine
was screened for diuretics and was negative. Final-
ly, it should be noted that patients with psychogenic
vomiting or diuretic abuse (so-called "pseudo-Bart-
ter's" syndrome) have increased excretory rates of
PGE2 [23, 41—43]. Since these patients share most of
the clinical and laboratory alterations seen in true
cases of the syndrome, it seems likely that in-
creased renal prostaglandin synthesis is a second-
ary rather than a primary abnormality.
Possible mechanisms of prostaglandin excess.
Table 5 lists some of the possible explanations for
secondary overproduction of prostaglandins in pa-
tients with Bartter' s syndrome. Plasma angiotensin
II is increased in the syndrome, and angiotensin II
is a potent stimulus of prostaglandin synthesis in the
kidney [37, 44, 45] and vasculature [46]. Since, as I
will discuss later, PGE2 and PGI2 are potent stimuli
of renin secretion and thereby increase plasma angi-
otensin II, it is impossible to know which alteration
is primary in these patients, i.e., increased renal
prostaglandin synthesis or increased angiotensin II
formation. Although methodologic difficulties can
obscure the absolute values, it appears that plasma
bradykinin is elevated in Bartter's syndrome [22].
Bradykinin stimulates prostaglandin synthesis in
most cells, including whole kidney [37, 45, 47] and
renal medullary interstitial cells [48]. Although un-
nary kallikrein also is increased in Bartter's syn-
drome [20, 22], urinary kinins are decreased [22].
Treatment with indomethacin suppresses plasma
bradykinin and urinary kailikrein; this suggests that
prostaglandins also might stimulate the kallikrein-
kinin-kininogen system [20, 22]. It is unknown
whether plasma vasopressin is elevated in untreated
Bartter' s syndrome, although chronic mild decre-
ments of effective circulatory volume could in-
crease plasma vasopressin. Studies in normal rats
and in rats with diabetes insipidus confirmed the
stimulatory effect of vasopressin on renal prosta-
glandin synthesis [49-51].
Controversy surrounds the possible importance
of potassium depletion as an explanation for en-
hanced renal prostaglandin synthesis [52]; Table 6
summarizes this issue. Galvez et a! reported that
potassium depletion in dogs augmented PGE2 ex-
cretion, caused polyuria and hyperreninemia, and
induced vascular resistance to angiotensin's pressor
action [53]. Additionally, in vitro studies with rabbit
renomedullary interstitial cells [54] and papillary
slices from rabbits and humans [55] showed aug-
mentation of PGE2 synthesis alter reductions in ex-
tracellular potassium. Using rats, Hood and Dunn
[56] as well as Berl et a! [57] were unable to detect a
change in PGE2 excretion [56] or renal meduilary
prostaglandin content [57] despite having induced
significant potassium depletion with accompanying
hypokalemia and polyuria. Furthermore, neither in-
domethacin nor meclofenamate improved the maxi-
mum urine osmolality in these experiments. Acute
potassium depletion (219 21 mEq negative bal-
ance) induced by treatment with furosemide for
three days did not increase PGE2 excretion in 5
healthy female volunteers [58]. Chronic potassium
depletion, accompanying primary aldosteronism
[59] or DOCA administration in humans [60], does
not increase renal excretion of PGE2. Hypokalemic
patients who have primary mineralocorticoid ex-
cess also have suppressed plasma angiotensin II
levels unlike patients with Bartter's syndrome,
those who self-induce vomiting, or those who abuse
Table 6. Potassium depletion and urinary PGE2
TableS. Possible causes of prostaglandin overproduction in
Bartter's syndrome
1. Increased plasma angiotensin II
2. Increased plasma bradykinin
3. Increased plasma vasopressin
4. Potassium depletion
5. Polyuria
1. Potassium depletion in dogs leads to increased urinary PGE2
2. Potassium depletion in rats leads to no changes in urinary
prostaglandins
3. Potassium depletion in humans due either to primary aldoste-
ronism or to DOCA administration leads to no changes of
urinary PGE2
4. In Bartter's syndrome, treatment with potassium salts can in-
crease urinary PGE2
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diuretics. Nasjletti et al came to a different con-
clusion regarding the effects of aldosterone and
DOCA on urinary PGE in the rat [61]; after 10 to 14
days of aldosterone or DOCA administration, they
found significant elevations of prostaglandin and
urinary kallikrein excretion [61]. Additionally, po-
tassium supplements (240 mEq per day) increased
rather than decreased PGE2 excretion in 2 patients
with Baflter's syndrome who also had increased
urine volumes [25]. Finally, there is little evidence
to suggest that potassium depletion directly stimu-
lates renal prostaglandin synthesis in vitro.
Polyuria, induced either by water loading or by
potassium or magnesium therapy, increases PGE2
excretion in humans [25] and dogs [62]; however,
polyuria in normal rats given 5% dextrose as drink-
ing water did not increase urinary prostaglandin ex-
cretion (Hood and Dunn, unpublished data). Most
patients with Bartter's syndrome have polyuria; it is
possible therefore that polyuria augments renal ex-
cretion of PGE2. These studies were performed in
patients who had polyuria of brief duration, how-
ever, and the relevance of these findings to a chron-
ic situation is unknown.
In summary, although it is likely that renal over-
production of prostaglandins in Bartter's syndrome
is a secondary event, we do not know what specifi-
cally triggers the increased prostaglandin synthesis.
Angiotensin II and bradykinin are plausible ex-
planations, but their primary role must be ques-
tioned because inhibition of prostaglandin synthesis
reduces plasma angiotensin II (i.e., plasma renin ac-
tivity) and bradykinin.
Renin, angiotensin, and aldosterone. Renin re-
lease by the kidney undoubtedly is partially con-
trolled by renal prostaglandin synthesis. Evidence
supporting this statement has come from experi-
ments in which renin secretion has been stimulated
by pro staglandins and prostaglandin precursors,
and also from experiments using inhibitors of pros-
taglandin synthesis. Arachidonic acid, infused into
the renal artery, stimulates renin secretion; how-
ever, arachidonic acid must be converted to prosta-
glandin since blockade of fatty acid cyclooxygenase
with indomethacin nullifies the renin stimulation by
arachidonic acid [63, 64]. Some disagreement exists
as to which prostaglandin is the critical stimulus to
renin release. It is possible, and indeed likely, that
several prostaglandins stimulate renin production
by the kidney. Evidence has been presented in ex-
perimental animals that PGI2, PGE2, and PGD2 can
increase renin secretory rates (Fig. 2). Yun and his
coworkers have shown that intrarenal infusions of
PGE2 and PGE1 increase renin secretion in anesthe-
tized dogs [65, 66]. Inhibition of endogenous renal
prostaglandin synthesis by pretreatment of the dogs
with indomethacin might explain the clear-cut stim-
ulation of renin release by PGE2, although prior
studies reported equivocal results. In the non-
filtering kidney, PGE2 retained its ability to stimu-
late renin secretion [67, 68]; this finding suggested
that prostaglandins act directly on juxtaglomerular
cells regardless of changes in delivery of glomerular
filtrate to the macula densa. Intrarenal infusion of
PGF2cr did not affect renin secretion. Hockel and
Cowley infused PGE2, 2 gImin, into the renal ar-
PGI2 PGE2
EndoperoxidesAldosterone
Renal kallikrein
1
Juxtaglomerular
cells
1' I
Inhibits Renin
Angiotensin 11
Vasocor,striction Direct Action
Arachidonic
Renal kininS Phospholipase Phospholipids ____ acid
activation
Baroreceptor 3-adrenergic
control control
Fig. 2. Interrelationship of prostaglandin, renin-angiotensin, and kallikrein-kinin systems. Indomethacin and similar drugs inhibit the
cyclooxygenase enzyme that converts arachidonic acid to endoperoxides (Data from Ref. 10).
PG Cyclo-
oxygenase
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teries of uninephrectomized dogs over a 7-day peri-
od [69]. Plasma renin activity increased rapidly, re-
mained elevated throughout the infusion, and was
strongly correlated with accompanying elevations
of mean arterial pressure. If prostaglandin over-
production were a primary abnormality in Bartter's
syndrome, one might expect similar responses,
namely hypertension with hyperreninemia. Gerber
et al also studied the role of prostaglandins as stimu-
li of renal renin release [67, 68, 70, 71]. To reduce
the effect of other mechanisms that control renin se-
cretion, they studied dogs that had undergone renal
denervation, had had pretreatment with propranolol
and indomethacin, and had a nonfiltering kidney.
Under these circumstances, PGE2 and PG!2 in-
creased renin secretion; PGE2 and PGI2 were either
equipotent renin stimuli [68] or PG!2 was more po-
tent [71]. Seymour et al confirmed that PGI2 and
PGD2 stimulate renin release from the kidney, re-
gardless of tubular flow to the macula densa [72,
73]. Since 13,14-dihydro-PGE2, a slowly metabo-
lized product of PGE2, was the most potent renin
stimulus, Gerber et al suggested that different rates
of prostaglandin degradation by the kidney might
account for the different potencies of PGE2 (rapidly
degraded) and PG!2 (slowly degraded) [71]. Two
groups were unable to show that rabbit cortical
slices incubated with PGE2 stimulate renin release
[74, 75], whereas PG!2 is stimulatory over concen-
trations of 10 to 10—7M [75]. Inhibitors of prosta-
glandin synthesis generally reduce but rarely oblit-
erate renal renin secretion. Reduction of renin re-
lease by indomethacin and other inhibitors of fatty
acid cyclooxygenase has been shown in normal ani-
mals and humans (1) under basal conditions; (2) af-
ter baroreceptor stimulation of renal juxtaglomeru-
lar cells; (3) after beta-adrenergic stimulation; and
(4) after administration of furosemide [76—83]. Re-
duction of plasma renin activity after indomethacin
administration can be variable, especially in sub-
jects with very low sodium intakes, e.g., 10 mEqI
day [77, 80]. There is uniform agreement that indo-
methacin, ibuprofen, and aspirin significantly re-
duce plasma renin activity in patients with Bartter' s
syndrome [14, 16, 17—26] as well as in patients with
surreptitious vomiting or diuretic abuse L23, 4 1—43].
Plasma renin activity decreased in the patient under
discussion after she received indomethacin therapy
(see Table 1; compare periods I and V).
Most patients with Bartter' s syndrome, as well as
those with covert vomiting, laxative abuse, or over-
use of diuretics, have secondary hyperaldostero-
nism. The extent of the increased aldosterone se-
cretion is blunted by the concomitant suppressive
effect of hypokalemia. Nonsteroidal inhibitors of
prostaglandin synthesis reduce or partially normal-
ize the excretory rates for aldosterone [22]. Glas son
et al also observed inhibitory effects of indometha-
cm on aldosterone excretory rates in normal indi-
viduals treated with spironolactone or given 10 to 15
mEq of sodium [82]. Although much of the suppres-
sion of aldosterone secretion is secondary to reduc-
tion of plasma renin activity, recent work suggests
that indomethacin directly inhibits aldosterone syn-
thesis in the adrenal gland. Campbell and co-
workers reported suppression by indomethacin of
angiotensin Il-stimulated aldosterone release in
vivo and in vitro with rat adrenal cells [83]. Miller,
Douglas, and Dunn have confirmed that indometha-
cm reduced aldosterone release by approximately
50% from purified preparations of rat adrenal zona
glomerulosa cells that had been stimulated by angi-
otensin II, ACTH, or potassium [84] (Fig. 3). Mec-
lofenamate produces similar results [84]. Although
these data suggest a direct role for prostaglandins in
aldosterone synthesis or release, Miller et al found
no increments in PGE synthesis by the adrenal cells
after stimulation of aldosterone production, and
arachidonic acid had no stimulatory action on al-
dosterone release despite a three- to fivefold in-
crement of PGE2 [84].
Patients with Bartter's syndrome and normal
pregnant women share many similarities (Table 7)
[85]. Pregnant women have increases in plasma re-
nm activity, angiotensin II, and aldosterone [86].
The vasculature is vasodilated in pregnancy, and
Bay and Ferris reported increased peripheral
plasma and urine concentrations of PGE2 [87]. Uri-
nary kallikrein also increases during pregnancy
[88]. Gant et al demonstrated resistance to the
pressor actions of angiotensin II during normal
pregnancy [89]. It is unknown whether increased
prostaglandin synthesis explains the resistance to
angiotensin!! in pregnancy. Patients with Bartter' s
and pseudo-Bartter's syndromes have a similar re-
sistance to the pressor actions of angiotensin I! and
norepinephrine [23]. Indomethacin given to preg-
nant women [90], patients with Bartter's syndrome
[20, 23, 91], or patients with surrepititious vomiting
[23] increases the pressor response to angiotensin
II. However, this finding does not provide direct
evidence of increased vascular synthesis of prosta-
glandins in these conditions because indomethacin
potentiates the pressor response to angiotensin I! in
normal individuals [92, 93]. Figure 4 shows the ef-
fect of 150 mg of indomethacin on the angiotensin
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Table 7. Similarities between Bartter's syndrome and normal
pregnancy
1. Increased plasma renin activity and angiotensin II
2. Increased aldosterone
3. Generalized vasodilation
4. 'Resistance" to angiotensin II
5. Indomethacin potentiates pressor response to angiotensin II
6. Increased urinary PGE2
7. Increased urinary kallikrein
400
Angiotensin II, ng/min
Fig. 4. Angiotensin II pressor responses in normal subjects. Ten
normal men (mean weight of 69.8 kg) received angiotensin II be-
fore and after indomethacin (50 mg every 6 hours for 3 doses).
Each dose of angiotensin was given intravenously for 20 minutes
(*p <0.025; **p <0.01) (Data from Ref. 92).
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who required an angioten sin II infusion rate of 25
5 ng/kg!min to increase blood pressure by 20 mm Hg
before indomethacin treatment, and 10 2 ng/kg/
mm after indomethacin [23]. Four patients with psy-
chogenic vomiting required 102 ng!kglmin to raise
their blood pressures 20 mm Hg; administration of
indomethacin returned sensitivity to normal (i.e., 12
2 ng/kglmin) [23].
In summary, abundant evidence exists that renal
synthesis of PGE2, PGFS, and 6-keto-PGF1,. is in-
creased in patients with Bartter's syndrome. There
are no data to support nonrenal or systemic over-
production of PGE2 or PGF2a,. Because a platelet
aggregation defect, reversible after indomethacin
administration, has been established in these pa-
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Fig. 3. Effects of indomethacin on aldosterone and PGE2 syn-
thesis in adrenal zona glomerulosa cells. Indomethacin, 3 X 10
M, was incubated with rat adrenal glomerulosa cells with angio-
tensin II, ACTH, or potassium. The percentage of PGE2 syn-
thesis remaining after indomethacin is indicated within the histo-
gram bars (Data from Ref. 84).
Il-induced increment in mean blood pressure in 10
normal men [92]. Indomethacin enhanced signifi-
cantly the vasoconstrictor action of angiotensin II
in these normal men. This response in healthy sub-
jects makes interpretation of similar tests in patients
with Bartter's syndrome difficult. In other words,
one should not assume that the diminished pressor
responsiveness to angiotensin II in patients with
Bartter' s syndrome is secondary to overproduction
of prostaglandins simply because indomethacin re-
verses the "resistance."
As anticipated, the woman we are discussing had
resistance to angiotensin as demonstrated by the in-
fusion test. The initial infusion rate of 90 ng!kglmin
required to raise the blood pressure by 20 mm Hg is
extremely high. When the test was repeated during
period II, a rate of 29 ng!kglmin was required,
which is also high. Indomethacin improved angio-
tensin sensitivity, but the value of 19 nglkglmin was
twice the normal value of 8 to 12 ng/kg!min. Radfar
et al reported 8 patients with Bartter's syndrome
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tients, some researchers have surmised that other
prostaglandins (e.g., PGI2, PGD2, 6-keto-PGE1) are
increased in plasma. The cause of the increased re-
nal synthesis of prostaglandins, although unknown,
seems clearly a secondary event in patients with
Bartter's syndrome. Drugs that inhibit fatty acid cy-
clooxygenase and thereby reduce prostaglandin
synthesis have a salutary effect in these patients.
Indomethacin and other nonsteroidal inhibitors of
prostaglandin synthesis reduce plasma renin activi-
ty and aldosterone excretory rates, reverse the vas-
cular insensitivity to angiotensin II, and increase
the plasma potassium.
Questions and answers
DR. JEROME P. KASSIRER: We now know a great
deal about derangements in the renin-angiotensin-
aldosterone system and the kallikrein-prostaglandin
system in patients with Bartter's syndrome, but our
understanding of the physiology fails to provide a
coherent, integrated picture of relations between
these disturbances. In your opinion, is this an accu-
rate reflection of the current situation?
DR. DUNN: I think it is. We do know enough to
say that prostaglandin overproduction is second-
ary, but we don't know how much of the renin ele-
vation is due to prostaglandin overproduction or
how much of the prostaglandin overproduction is
due to renin elevation. We can best integrate this
information by saying that the primary abnormality
is tubular: either a chloride reabsorptive defect in
the thick ascending limb or a potassium reabsorp-
tion defect in the distal tubule. How would those
events trigger prostaglandin overproduction? You
are absolutely right that we understand many phys-
iologic and pathophysiologic interrelations but that
we do not understand the temporal and sequential
mechanisms.
DR. KASSIRER: You implied that potassium deple-
tion could be excluded as the cause of prostaglandin
overproduction, but I am not convinced that the
models of potassium depletion studied approxi-
mated closely the physiologic state of patients with
Bartter' s syndrome. In animals treated with miner-
alocorticoids and in patients with primary aldoste-
ronism, for example, volume tends to be expanded,
whereas in patients with Bartter's syndrome, vol-
ume is probably normal or low.
DR. DUNN: That's Tight. Those animals are im-
perfect models of potassium depletion because they
are volume expanded, have aldosterone or DOCA
excess, and have suppressed renin and angiotensin
levels, whereas the patient with Bartter's syndrome
has either normal or slightly low plasma volume and
very high levels of renin and angiotensin. Research-
ers at several laboratories agree that dietary potas-
sium depletion in rats does not increase renal pros-
taglandin overproduction, but these studies might
be inapplicable to humans.
DR. KASSIRER: Was potassium deficiency in-
duced by administration of DOCA in these experi-
ments?
DR. DUNN: Potassium depletion was induced via
dietary deprivation; although potassium deprivation
generally increases plasma renin activity, we did
not measure plasma renin in these experiments.
DR. JORDAN J. COHEN: As you noted, Gill and
Bartter hypothesized that the fundamental defect in
Bartter's syndrome involves the chloride transport
mechanism in the ascending limb [38]. Do we know
how prostaglandins affect chloride transport in the
kidney? Also, do prostaglandin synthetase inhib-
itors alter the chloride transport defect in Bartter's
syndrome?
DR. DUNN: I don't know whether all the answers
to that question are in. If the chloride reabsorptive
defect is a primary abnormality, and researchers
disagree about that, you could theorize that the de-
fect results from prostaglandins, because PGE2
does inhibit chloride reabsorption in the micro-
perfused thick ascending limb in the rabbit [39]. Hi-
gashihara and coworkers have shown that acute re-
duction of prostaglandin synthesis augments chlo-
ride reabsorption in the rat [40]. These data suggest
that prostaglandins inhibit the movement of chlo-
ride from the luminal fluid out of the tubule in the
thick ascending limb and perhaps more distal seg-
ments. Gill and Bartter studied chloride reabsorp-
tion in Bartter's syndrome before and after indo-
methacin administration. Because indomethacin did
not improve the chloride reabsorptive defect, they
concluded that excessive prostaglandins did not ex-
plain the chloride transport abnormality [38]. I ne-
glected to emphasize the importance of measuring
urinary chloride to differentiate patients with Bart-
ter's syndrome, whose urinary chloride levels
should approximate the dietary intake, from pa-
tients with covert or surreptitious vomiting, in
whom urinary chloride is very low. In most other
respects, the patient with self-induced vomiting can
mimic the patient with Bartter's syndrome and even
can manifest a beneficial response to indomethacin.
Patients who are diuretic abusers have high urinary
chloride levels and therefore mimic even more
closely patients with Bartter's syndrome. You must
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rule out diuretic abuse by assaying the urine for di-
uretics because patients are not always forthright
about the medications they take.
DR. JEFFREY S. STOFF (Renal Unit, Beth Israel
Hospital, Boston, Mass.): I would like to comment
on several aspects of Dr. Dunn's superb presenta-
tion. One of the issues he raised concerns the ques-
tion of whether the increase in urinary prostaglan-
din excretion in Bartter's syndrome is a primary or
secondary event. The recent observation by Drs.
Gill and Bartter suggests that the chloride reabsorp-
tion defect is independent of prostaglandins since it
was not reversed by treatment with indomethacin
[38]. However, indomethacin treatment generally
fails to fully suppress urinary prostaglandin excre-
tion to normal in these patients. The failure to re-
verse the defect in chloride transport by indometha-
cm thus still might be the result of increased
amounts of prostaglandins acting on tubular trans-
port. In fact, several reports have indicated that
PGE2 inhibits chloride transport at the thick ascend-
ing limb of Henle's loop [39, 40].
Secondly, the effect of potassium on regulation of
prostaglandin metabolism remains controversial,
with conflicting data derived from several different
models. The studies by Drs. Dunn and Berl utilizing
the potassium-depleted rat failed to demonstrate an
increase in PGE2 excretion [56, 57], whereas Ferris
and colleagues reported an increase in PGEZ excre-
tion in the potassium-depleted dog [94]. These latter
studies agree with the findings by Zusman and Kei-
ser on the effect of potassium on renal medullary
interstitial cells grown in tissue culture [95]. We
have explored this question in humans by inducing
potassium depletion using a potassium-restricted
diet and a cation-binding resin (Kayexalate®) [96].
We successfully induced a reversible defect in uri-
nary concentrating ability in these acutely potas-
sium-depleted subjects. However, PGE2 excretion
did not increase with, nor was the defect corrected
by, indomethacin treatment. These results thus
failed to provide evidence for potassium depletion
as a cause of increased PGE2 excretion in humans.
DR. KASSIRER: What was the extent of the potas-
sium deficiency in these experimental subjects?
DR. STOFF: Serum potassium decreased an aver-
age of 1 mEq/liter, and total-body potassium count-
ing indicated a 10% to 12% decline, but the latter
result was quite variable. The concentrating defect
was about 30% to 40% of maximal concentrating
ability.
DR. DUNN: Your findings are interesting, Dr.
Stoff, because we tried unsuccessfully to reverse
the concentrating defect with meclofenamate in po-
tassium-depleted rats. Berl, Aisenbery, and Linas
reported a similar lack of effect of indomethacin on
urine concentration in potassium-depleted rats [57].
DR. KASSIRER: I presume, therefore, that in your
potassium-depleted subjects the serum potassium
concentration was approximately 3 mEq/liter. Of
course, because patients with Bartter's syndrome
frequently have lower serum potassium concentra-
tions and, by inference, greater potassium deficits
than did the subjects you studied, it is still possible
that a greater degree of potassium deficiency could
be responsible for the prostaglandin abnonnalities.
I am not an advocate of the notion that potassium
deficiency is the proximate cause of prostaglandin
overproduction in Bartter's syndrome, but I am not
willing to dismiss this hypothesis without more con-
vincing evidence.
DR. RANDALL ZUSMAN (Cardiac Unit, Massa-
chusetts General Hospital, Boston, Mass.): When
Bartter's syndrome was first known to be associat-
ed with elevated PGE2 excretion, it was assumed
that prostaglandin overproduction was a proximal
event in the pathogenesis of the disorder. Further
investigation disclosed, however, that prostaglan-
din overproduction was not causative. The data
from Ferris' laboratory provided evidence in the
dog that hypokalemia itself was the stimulant to
PGE2 overproduction [53], but data from your lab
indicated that hypokalemia had no effect on urinary
PGE2 excretion in the rat [56]. We have shown that
rabbit renomedullary interstitial cells incubated in
potassium-free buffered solution synthesize larger
amounts of PGE2 than do cells incubated in potas-
sium-containing buffers [48, 95]. These data suggest
that acute potassium depletion stimulates PGE2 ex-
cretion in vitro. Subsequent work by Dusing, who
used rabbit renomedullary slices, also demon-
strated that potassium depletion stimulates PGE2
synthesis in vitro [55]. Can you reconcile these ap-
parent differences or add any more information
about the rat interstitial cell in vitro? Does it re-
spond like the rabbit interstitial cell? How can we
integrate the in vivo and in vitro data?
DR. DUNN: We have not done experiments alter-
ing extracellular potassium in the rat medullary in-
terstitial cell, so I really don't know. How much did
you change the extracellular potassium in order to
effect a change in PGE2 production by the inter-
stitial cell? Was it in the range of 5 to 10 mmol?
DR. ZUSMAN: If PGE2 synthesis is measured in
the rabbit renomedullary interstitial cell in tissue
culture, and the potassium concentration in the me-
dium is varied from 2 to 7 mEq/liter, PGE2 synthesis
is inhibited approximately 7% for each 1 mEq/liter
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increase in potassium concentration [98]. At potas-
sium concentrations below 2 mEq/liter, there is a
striking increase in prostaglandin synthesis. These
experiments test the effects of acute potassium de-
pletion, but we do not know the intracellular potas-
sium concentration under these conditions. As Dr.
Kassirer implied before, the chronic potassium de-
pletion that characterizes patients with Bartter's
syndrome and those who vomit surreptitiously
might result in a profound intracellular potassium
deficit and in increased PGE2 excretion.
DR. DUNN: I cannot reconcile the differences be-
tween the in vitro results you quote and the difil-
culty with in vivo results; only one laboratory has
shown in the dog—and nobody else has been able to
show in humans or rats—that negative potassium
balance stimulates prostaglandin synthesis. I agree
that these negative results might be accounted for
by the modest potassium depletion induced in the
experiments I alluded to.
DR. ZUSMAN: I doubt that species differences ac-
count for these disparate results. To postulate that
the rat is more resistant to potassium depletion than
is the rabbit is not a satisfactory explanation.
DR. ROBERT S. BROWN (Chief, Renal Unit, Beth
Israel Hospital, Boston, Mass.): I would like to add
some evidence from our laboratory that tends to ex-
clude hypokalemia as the primary stimulus for the
increase in prostaglandins in Bartter's syndrome.
We have used platelet aggregometry to identify a
prostaglandin-like substance in the plasma of pa-
tients with Bartter's syndrome. This substance can
induce an aggregation defect in platelets from
healthy individuals as well as in those who have
Bartter's syndrome. We have studied small num-
bers of patients who abuse diuretics and those with
surreptitious vomiting; both groups had comparable
degrees of hypokalemia but in neither were we able
to demonstrate a defect. The platelet defect is not
present in patients with primary hyperaldosteronism
or in potassium-depleted normal individuals; this
prostaglandin-like factor therefore seems to be
unique to Bartter' s syndrome rather than secondary
to potassium depletion.
Dr. Dunn questioned the effect of indomethacin.
Indomethacin, a complex drug, has a variable inhib-
itory action on different cyclooxygenases. It is
known that some cyclooxygenases are more resis-
tant to indomethacin, and we should not assume
that if urinary PGE2 is decreased by 80% that other
prostaglandins also will be reduced by 80%; other
prostaglandins might be reduced by much less than
80%. For instance, the platelet aggregation defect in
patients with Bartter's syndrome who are on low-
sodium diets is alleviated only slightly by indometh-
acm, whereas urinary PGE2 is greatly reduced to
normal levels. The administration of indomethacin
decreases urinary prostaglandins in these patients
but fails to correct the platelet defect caused by a
prostacyclin-like substance in the plasma [21].
DR. DUNN: Have you observed a platelet aggre-
gation defect in relatives of patients with Bartter's
syndrome?
DR. BROWN: We haven't looked at normal rela-
tives, but the familial occurrence of Bartter' s syn-
drome is well known. It is a good suggestion to
study the family members who do not clinically ap-
pear to have Bartter's syndrome.
DR. DUNN: Has the platelet defect been a consis-
tent finding?
DR. BROWN: Only in patients who have Bartter's
syndrome.
DR. STOFF: I would like to comment on our stud-
ies with the circulating plasma factor in Bartter' s
syndrome [21]. We have neutralized the anti-
aggregatory effect of the plasma factor with antisera
directed against PGI1 [96]. These sera crossreact
with pro stacyclin and 6-keto PGE1 and to a lesser ex-
tent with 6-keto F1. We are now generating an anti-
serum to 6-keto PGE1 to test whether this circulat-
ing plasma factor is in fact 6-keto PGE1. We think that
these studies support the idea that prostacyclin me-
tabolites are present in high concentration in the
plasma of patients with Bartter' s syndrome and that
these substances contribute to the high renin state
as well as to the defect in platelet function.
DR. DUNN: Would you agree with my inter-
pretation of your published data that the plasma fac-
tor that induced the platelet aggregation defect in
normal platelets cannot be prostacyclin because,
unlike prostacyclin, it was stable for more than one
hour during the incubation?
DR. STOFF: You are right. There is little doubt
that the circulating factor is not prostacyclin, as the
plasma factor is much more stable.
DR. AARON SPITAL (Renal Unit, Rhode Island
Hospital, Providence, Rhode Island): Is it possible
that the vascular insensitivity in patients with Bar-
tter' s syndrome is related to the high levels of circu-
lating angiotensin? Also, does indomethacin reduce
these high levels of angiotensin and thereby free up
receptors that previously might have been saturat-
ed?
DR. DUNN: That is a good question. We know
that the higher the endogenous renin level, the less
sensitive is the vasculature to infused angiotensin
II, as the receptor occupancy from endogenous an-
giotensin II is high. Patients with Bartter's syn-
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drome have similar vascular insensitivity to norepi-
nephrine; I think that vascular insensitivity to ang-
iotensin II in patients with Bartter's syndrome
cannot be explained solely by angiotensin II recep-
tor occupancy.
DR. JOHN T. HARRINGTON: What happens to the
platelet defect in a patient with Bartter's syndrome
in whom sodium intake is restricted to 7 to 10 mEq/
day? Is either the platelet dysfunction or the in-
crease in prostaglandin synthesis negated?
DR. BROWN: The platelet defect persists. In fact,
sodium restriction worsens the platelet defect even
though the prostaglandins (PGE2) decrease in the
urine.
DR. NICOLAOS MADIAS Renal Service,
NEMCH): Has anyone studied patients with Bart-
ter's syndrome following either acute or chronic in-
terruption of the renin-angiotensin system with, for
example, a converting enzyme inhibitor? What hap-
pens to their blood pressure and their aldosterone
levels?
DR. DUNN: Rudin et al reported that blood pres-
sure is very dependent on the angiotensin II levels
and that these patients are quite sensitive to sarala-
sin. Indomethacin reversed the vasodepressor ef-
fects of saralasin in 2 patients [26].
DR. MADIAS: What happens to the prostaglandin
level?
DR. DUNN: To my knowledge, no one has mea-
sured PGE2 before and after saralasin administra-
tion in patients with the syndrome.
DR. ANDREW LEVEY (Renal Fellow, NEMCH):
Is urinary prostaglandin excretion elevated in other
hyperreninemic states such as cardiac failure, cir-
rhosis, nephrotic syndrome, and volume depletion?
Are these clinical disorders characterized by hyper-
reninemia but not with an increase in urinary PGE
excretion?
DR. DUNN: There have been no reports of meas-
urements of prostaglandins in congestive heart fail-
ure, but one study did report that patients with
congestive failure who are given indomethacin can
have precipititous decreases in renal function [98].
Boyer, Zia, and Reynolds [99] and Zipser and his
collaborators [100] reported that urinary prostaglan-
dins were increased in patients with cirrhosis and
ascites and that after indomethacin or ibuprofen ad-
ministration, the patients had decreases in renal
blood flow and GFR. Zambraski and I are studying
the effects of chronic bile duct ligation in dogs on re-
nal susceptibility to indomethacin. Within 60 to 90
days of biliary ligation, a single, intravenous dose of
indomethacin, 2 mg/kg, causes reductions of renal
blood flow and GFR (unpublished results). Condi-
tions associated with decreases in effective circulat-
ing volume, such as sodium depletion, nephrosis,
heart failure, and cirrhosis with ascites, are associ-
ated with high plasma angiotensin II and increased
alpha-adrenergic activity as compensatory re-
sponses. A greater need exists, therefore, for renal
prostaglandins to modulate these constrictor influ-
ences. If you interrupt prostaglandin synthesis with
indomethacin, renal function is compromised. Pa-
tients with Bartter' s syndrome, similarly, have high
angiotensin II levels; most series that have mea-
sured GFR before and after indomethacin treatment
have shown a 10% to 25% decrement in GFR,
sometimes transient and sometimes fixed.
DR. LEVEY: Should we interpret elevated urinary
PGE as a sign of hyperrenemia?
DR. DUNN: In general, plasma renin activity and
urinary prostaglandins are positively correlated, es-
pecially in disease states. But some researchers
have found that salt depletion in normal humans has
no effect on urinary prostaglandins. Dr. Zusman,
did you find increments of urinary PGE2 after so-
dium depletion of normal subjects?
DR. ZUSMAN: No, we did not find an effect of
dietary sodium content on urinary PGE2 excretion
[22]. I had some reservations, however, about the
validity of the assay for urinary PGE2, and therefore
I think that the effect of sodium intake on urinary
prostaglandin excretion has to remain an open ques-
tion for now.
DR. COHEN: Why did salt depletion in this patient
cause urinary prostaglandins to increase?
DR. DUNN: Urinary prostaglandins certainly did
increase with salt depletion (period IV), probably
because the plasma angiotensin II increased and
possibly because there were increments in plasma
bradykinin as a result of the aldosterone stimula-
tion.
DR. SPITAL: What is the evidence that vasopres-
sin stimulates prostaglandin production?
DR. DUNN: The evidence for that can be found in
several systems. Dr. Zusman showed that rabbit re-
nomedullary interstitial cells in vitro increase PGE2
synthesis in response to arginine vasopressin [48].
We and a group from Vanderbilt have published
work on rats with diabetes insipidus (Brattleboro
rat) showing that these animals, which lack vaso-
pressin, have much lower urinary excretion of
PGE2 and PGF1a [49-51]. We treated the rats with
pitressin tannate in oil or with dD-AVP, a vasopres-
sin analogue without pressor activity. We found
that vasopressin treatment for as little as one or two
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days in the Brattleboro rat increases urinary prosta-
glandin excretion about threefold [49]. We recently
extended those studies in collaboration with Drs.
Kinter and Beeuwkes at Harvard Medical School.
There was a linear dose-response relationship be-
tween dD-AVP and urinary PGE2; the evidence is
quite good, at least in the rat model, that renal pros-
taglandins are stimulated by vasopressin [50]. No
similar evidence is available in humans.
DR. MADIAS: Has anyone observed pregnant pa-
tients with Bartter's syndrome? The similarities be-
tween the syndrome and pregnancy prompt me to
ask whether such patients have any hormonal or he-
modynamic changes during pregnancy as compared
to baseline.
DR. DUNN: I know of no studies of pregnant pa-
tients who have Bartter's syndrome. I am puzzled
by the difference between pregnancy and Bartter's
syndrome, because hormonally these women are
similar. Perhaps the antialdosterone effect of pro-
gesterone is important.
DR. KASSIRER: Another difference is the lack of a
renal chloride wasting defect in the normal pregnant
woman.
DR. COHEN: I understand why you think the
changes in prostaglandins are secondary in Bait-
ter's syndrome. I also understand that indometha-
cm has effects other than those occurring via the
prostaglandin system. But I am still puzzled by the
improvement that most, if not all, patients with
Bartter' s syndrome experience when given indo-
methacin. If prostaglandins are not intimately in-
volved in the pathogenesis of the electrolyte distur-
bance, how can you explain the improvement that
occurs?
Da. DUNN: I didn't say that the elevation of pros-
taglandins was unimportant in Bartter' s syndrome;
I only said it was secondary. If the prostaglandins,
renin, and aldosterone are reduced, the potassium
balance becomes positive. These people feel poorly
largely because they are potassium depleted. If one
raises the potassium levels in these patients by re-
ducing renin via reductions of prostaglandins, they
feel better.
DR. COHEN: But aren't you also suggesting that
positive feedback drives prostaglandin production
in this syndrome?
DR. DUNN: Yes. Prostaglandins stimulate renin
and angiotensin, and renin stimulates prostaglandin
production.
DR. COHEN: What stops it?
DR. DUNN: Probably the negative feedback of an-
giotensin II on renin production by the juxtaglo-
merular cells. Ultimately, a new steady state is es-
tablished in which a high angiotensin II level inhib-
its renin production despite continued production of
prostaglandin.
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